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Abstract
Background: Coronavirus disease 2019 (COVID-19) is associated with acute respiratory distress syndrome, and
corticosteroids have been considered as possible therapeutic agents for this disease. However, there is limited
literature on the appropriate timing of corticosteroid administration to obtain the best possible patient outcomes.
Methods: This was a retrospective cohort study including patients with severe COVID-19 who received
corticosteroid treatment from March 2 to June 30, 2020 in seven tertiary hospitals in South Korea. We analyzed the
patient demographics, characteristics, and clinical outcomes according to the timing of steroid use. Twenty-two
patients with severe COVID-19 were enrolled, and they were all treated with corticosteroids.
Results: Of the 22 patients who received corticosteroids, 12 patients (55%) were treated within 10 days from diagnosis.
There was no significant difference in the baseline characteristics. The initial PaO2/FiO2 ratio was 168.75. The overall
case fatality rate was 25%. The mean time from diagnosis to steroid use was 4.08 days and the treatment duration was
14 days in the early use group, while those in the late use group were 12.80 days and 18.50 days, respectively. The
PaO2/FiO2 ratio, C-reactive protein level, and cycle threshold value improved over time in both groups. In the early use
group, the time from onset of symptoms to discharge (32.4 days vs. 60.0 days, P = 0.030), time from diagnosis to
discharge (27.8 days vs. 57.4 days, P = 0.024), and hospital stay (26.0 days vs. 53.9 days, P = 0.033) were shortened.
Conclusions: Among patients with severe COVID-19, early use of corticosteroids showed favorable clinical outcomes
which were related to a reduction in the length of hospital stay.
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Background
Coronavirus disease 2019 (COVID-19), a disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was first reported in China in late 2019 [1]. It has af-
fected almost 25 million people worldwide, and resulted in
the deaths of more than 850,000 as of August 31, 2020 [2].
The majority of infected patients are asymptomatic and show
only mild symptoms; however, the remainder of patients ex-
perience a severe form of the disease. Elderly patients and pa-
tients with underlying diseases, such as diabetes mellitus,
hypertension, and immunosuppressive disorders, have con-
siderable morbidity and mortality when co-infected with
COVID-19 [3, 4]. The overall fatality rate is approximately
0.4–2.0%, but may be up to 50% in patients with life-
threatening illnesses [5], a finding which suggests that it is
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necessary to use different treatment approaches in these
patients.
Severe COVID-19 is accompanied by inflammatory organ
injury and causes acute respiratory distress syndrome, shock,
or cardiac failure due to elevated levels of inflammatory cyto-
kines and biomarkers. These include C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), ferritin, and D-
dimer [6, 7]. Although the main pathophysiology of COVID-
19 is not completely understood, excessive inflammation is
closely related to the development of pneumonia and rapid
progression of the disease [6, 8]. Anti-inflammatory treat-
ments, such as corticosteroids, are therefore, therapeutic op-
tions for severe COVID-19 [9].
Several potential therapeutics have been proposed in
the early phase of the COVID-19 pandemic, such as
chloroquine, hydroxychloroquine, lopinavir/ritonavir,
azithromycin, intravenous immune globulin, and conva-
lescent plasma transfusion; but corticosteroids and
remdesivir have been known to improve clinical out-
come so far [10, 11].. Corticosteroid, especially methyl-
prednisolone, have been widely used in patients with
severe COVID-19 cases in South Korea before the
WHO and CDC made recommendations against using
corticosteroid. Although some studies have shown that
the usefulness of corticosteroid is limited [12–14], it has
still become a potentially good therapeutic option as
other studies, including the RECOVERY trial [11], have
demonstrated beneficial effects of corticosteroid use
[15–18]. The RECOVERY trial is a large-scale, prospect-
ive, well-designed study, which demonstrated that the
use of dexamethasone reduces mortality in patients with
severe COVID-19 [11]. Other types of corticosteroids,
such as hydrocortisone [19], have also been demon-
strated to improve clinical outcomes [20]. The use of
corticosteroids could theoretically cause several side ef-
fects [21], but did not inhibit secondary bacterial infec-
tion or viral clearance [22, 23]. Strong evidence for
dexamethasone use has been suggested from the RE-
COVERY trial. Because this trial has strong evidence for
corticosteroid use, relatively fewer other studies were
conducted. As a result, there is insufficient data to deter-
mine which types of corticosteroid (dexamethasone,
hydrocortisone, methylprednisolone) are more beneficial
[20], and the appropriate duration [24] and timing to
start corticosteroid use still remain controversial.
This study aimed to analyze the results in groups with
early and late use of corticosteroids to determine the
right timing of corticosteroid use in patients with severe
COVID-19.
Methods
Study design and population
This was a retrospective cohort study of patients with
severe cases of COVID-19 who received corticosteroid
treatment between March 2 and June 30, 2020 in seven
tertiary hospitals in South Korea. The current study in-
cluded patients aged ≥18 years with laboratory-
confirmed SARS-CoV-2 infection who were admitted to
the ICU. Patients with insufficient clinical data due to
hospital transfers were excluded.
Electronic medical records were reviewed for baseline
demographics, comorbidities, clinical characteristics,
clinical status, laboratory findings, treatment, clinical
course, and outcomes. Data were compared before ster-
oid use, as well as 3, 7, and 14 days later.
This study was conducted in accordance with the
guidelines of the Declaration of Helsinki and approved
by the Institutional Review Boards of Severance Hospital
(Seoul, South Korea). The requirement for informed
consent was waived because of the retrospective nature
of the study. All data was anonymized to keep the confi-
dentiality of the patient’s personal information during
the entire research process including patient data collec-
tion, analysis and writing.
Definition
SARS-CoV-2 RNA was assessed by real-time reverse
transcription polymerase chain reaction (RT-PCR) of
nasopharyngeal swabs or sputum according to the
World Health Organization interim guidance. RT-PCR
assays for the E, RdRp, and N genes were performed
using the Allplex™ 2019-nCoV Assay (Seegene Inc.,
Seoul, South Korea). Positive RT-PCR results were de-
fined as a cycle threshold (Ct) value ≤40. The severity
was assessed by PaO2/FiO2 ratio and categorized into
seven scores based on oxygen supplementation: no limit
of activity, limit of activity but no O2, O2 with nasal
prong, O2 with facial mask, high flow nasal cannula,
noninvasive ventilation, and invasive ventilation.
The patients were divided into two groups by the time
to corticosteroid use. Patients who were treated with
corticosteroids within 10 days and after 10 days of con-
firmation were categorized as the early use group and
the late use group, respectively.
CRP concentration was measured in serum using a
nephelometric method (Beckman Coulter, Fullerton, CA,
USA).
Statistical analysis
Continuous variables were examined for normality by
Kolmogorov-Smirnov test. Continuous variables with
normal distribution were shown as the mean ± standard
deviation (SD). Group comparisons were performed
using independent two-sample t-test. Continuous non-
normal distribution variables were shown as the median
interquartile range (3rd interquartile range-1st inter-
quartile range), and Mann-Whitney U tests were used to
compare the differences between groups. Categorical
Hyun et al. BMC Infectious Diseases          (2021) 21:506 Page 2 of 8
variables were shown as numbers (percentages). Chi-
squared tests and Fisher’s exact test were used to com-
pare categorical data in different groups. Laboratory
findings were analyzed based on a linear mixed model
using groups (early or late) and time (after corticosteroid
administration) and an interaction between groups and
time. Spearman’s correlation coefficient was calculated
to analyze correlation of variables. Statistical significance
was set at P < 0.05. All statistical analyses were per-
formed using the Statistical Package for the Social Sci-
ences version 25.0 (IBM Corporation, Armonk, NY,
USA).
Results
During the study period, 22 patients who met the inclu-
sion criteria were categorized into the early use group
(n = 12) or the late use group (n = 10). The baseline
demographics and characteristics of each group were
similar (Table 1). The mean age of the early use group
was 65.6 years, and 50% were male. Among them, seven
patients (58.3%) had a history of hypertension. The most
common symptoms were fever (75%), cough (50%), spu-
tum (41.7%), dyspnea (41.7%), and fatigue (41.7%). Pa-
tients were assessed based on an ordinal scale; four
patients (33.3%) had a score of 2 (limit of activity but no
O2); five (41.7%) had a score of 3 (O2 with nasal prong),
and three (25%) had a score of 5 (high flow nasal can-
nula). Baseline laboratory tests were similar between the
two groups. The initial PaO2/FiO2 ratio in the early use
group was 124.89. The inflammatory markers were ele-
vated; the mean levels of ferritin, ESR, and CRP were
804.22 ± 601.11 ng/mL, 60.00 ± 35.78, and 10.33 ± 8.95,
respectively.
The therapeutic options and timing differences of pa-
tients are shown in Table 2. Most patients used methyl-
prednisolone, and only one patient used hydrocortisone.
Corticosteroids were initiated within a median of 9.75 ±
3.64 days of the onset of symptoms, 3.00 (2.00–7.00)
days of the confirmation, and 3.33 ± 3.45 days after hos-
pital admission. The initial dose of corticosteroid admin-
istered was 0.81 (0.50–1.00) mg kg− 1 day− 1
methylprednisolone, and patients were treated for
14.00 ± 5.00 days. The total dose administered was
521.6 ± 246.38 mg methylprednisolone.
Table 3 shows the comparison of laboratory findings
before and after corticosteroid use. Significant changes
in lymphocyte count, lactate dehydrogenase, and inflam-
matory markers (ferritin, CRP, and procalcitonin) were
observed after corticosteroid administration in both
groups. The PaO2/FiO2 ratio and Ct value improved in
both groups. However, when comparing changes be-
tween the two groups, there was no significant difference
in improvement (Fig. 1).
Table 4 shows the comparison of clinical outcomes be-
tween the two groups. The duration of hospital stay was
shorter in the early use group than in the late use group
(26.0 ± 11.4 vs. 53.9 ± 23.0 days, P= 0.033). The time from
corticosteroid use to discharge was 25.6 days in the early use
group and 46.3 days in the late use group, but the difference
was not significant (P= 0.096). We could not demonstrate a
correlation between the time between diagnosis and cortico-
steroid use, and the duration of hospital stay (R2 = 0.143, P=
0.213) (Fig. 2). There was no significant difference in the
overall mortality. None of the patients in either group suf-
fered secondary bacterial infection or hyperglycemia.
Discussion
The COVID-19 pandemic has been worsening and
spreading worldwide. Although many types of treatment,
Table 1 Comparisons of baseline demographics and
characteristics in patients with severe COVID-19
Characteristics Early use group
(n = 12)
Late use group (n =
10)
Age (years) mean ± SD 65.6 ± 5.6 74.6 ± 4.6
Sex, No. (%)
Male 6/12 (50%) 6/10 (60%)
Coexisting disease, No. (%)
Hypertension 7/12 (58.3%) 4/10 (30%)
Diabetes 3/12 (25%) 3/10 (30%)
Malignant neoplasm 2/12 (16.7%) 1/10 (10%)
Symptoms
Fever 9/12 (75%) 7/10 (70%)
Cough 6/12 (50%) 3/10 (30%)
Sputum 5/12 (41.7%) 4/10 (40%)
Dyspnea 5/12 (41.7%) 4/10 (40%)
Myalgia 5/12 (41.7%) 2/10 (20%)
Fatigue 5/12 (41.7%) 1/10 (10%)
Poor oral intake 4/12 (33.3%) 1/10 (10%)
Initial score on ordinal scale
No limit of activity 0 0
Limit of activity but
no O2
4/12 (33.3%) 4/10 (40%)
O2 with nasal prong 5/12 (41.7%) 2/10 (20%)
O2 with facial mask 0 0
High flow nasal
cannula




Invasive ventilation 0 0
Baseline score missing 0 1/10 (10%)
Initial PaO2/FiO2 ratio 124.89 ± 42.60 133.35 ± 49.40
COVID-19, coronavirus disease 2019; SD, standard deviation
Data are expressed as mean ± SD or number (%)
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including chloroquine, hydroxychloroquine, lopinavir/ri-
tonavir, azithromycin, intravenous immune globulin, and
convalescent plasma transfusion, have been used in the
early phase of COVID-19 pandemic, they have been
proven to be ineffective and are no longer used. An anti-
viral agent like Remdesivir [11], as well as immunomod-
ulatory agents such as Tocilizumab (IL-6 inhibitor) [25]
and Baaricitinib (JAK inhibitor) [26], and monoclonal
antibodies like Bamlanivimab [27], and Casirivimab/
imdevimab [28] can be used to treat patients with
COVID-19. However, these types of medicine have been
found to be less useful in critically ill patients with
COVID-19, so additional treatment options are still
needed for patients with severe COVID-19.
Corticosteroids have long been considered to be effect-
ive in patients with acute respiratory distress syndrome,
septic shock, and possibly viral pneumonia [29]; but this
is still controversial. An interim guidance document re-
leased on May 27, 2020 by the World Health
Organization on clinical management of COVID-19 rec-
ommended against the routine use of systemic cortico-
steroids for the treatment of viral pneumonia. The
Infectious Disease Society of America recommends the
use of corticosteroids in the context of clinical trials for
patients with acute respiratory distress syndrome [30].
However, adherence to this recommendation remains
low, with many studies suggesting opposite results. Stud-
ies favoring the use of corticosteroids began with the
RECOVERY trial, which demonstrated that intravenous
dexamethasone (6 mg daily for 10 days) reduced 28-day
mortality in hospitalized patients with COVID-19 re-
quiring oxygen therapy or mechanical ventilation [11].
This landmark trial has been supported by another trial
[19, 31, 32] and meta-analysis [15, 17, 18, 33]. These
studies provide evidence on the effectiveness of cortico-
steroid, suggest a safe treatment option for COVID-19,
and have changed our clinical practice regarding patients
with severe COVID-19.
The pathogenesis of severe COVID-19 still remains
unclear, but it is believed to have two overlapping patho-
logic subsets, similar to other types of viral pneumonia.
In the early stage of infection, as SARS-CoV-2 replicates,
mild clinical manifestations such as fever, malaise, and
cough are observed. In most of these cases, patients re-
cover without therapeutic support; but in other cases,
they progress to severe disease. This is a result of host
systemic inflammation rather than direct viral-induced
tissue damage. Since sepsis and other critical illnesses
occur for approximately 10 days [3], the maladaptive
host response to the viral infection starts during this
period. For this reason, anti-inflammatory therapy, such
as corticosteroids, is not recommended for early use.
Many studies have shown that corticosteroids can pro-
long viral shedding and cause secondary infections [34–
36]. In our study, patients were divided into two groups
based on the duration from diagnosis to corticosteroid
use on a 10-day basis. Both groups showed increasing Ct
values after corticosteroid use. Within each group, the
Table 2 Factors associated with therapeutic option in patients with severe COVID-19
Early use group (n = 12) Late use group (n = 10) p-value
Combination therapy
Steroid 7/12 (58.3%) 8/10 (80.0%) 0.162
Steroid + Convalescent plasma 5/12 (41.7%) 1/10 (10.0%)
Steroid + Remdesivir 0 1/10 (10.0%)
Steroid-related factor
Time from symptom to steroid use 9.75 ± 3.64 15.70 ± 6.00 0.010
Time from diagnosis to steroid use 3.00 (2.00–7.00) 12.5 (11.00–14.25) < 0.001
Time from hospitalization to steroid use 3.33 ± 3.45 10.00 ± 4.83 0.001
Initial dosea, mg/kg/day 0.81 (0.50–1.00) 1.00 (0.76–.1.00) 0.456
Duration, days 14.00 ± 5.00 18.50 ± 14.76 0.380
Total dosea, mg 521.6 ± 246.38 667.50 ± 606.76 0.490
Score on ordinal scale at steroid start 0.035
O2 with nasal prong 1/8 (12.5%) 0
High flow nasal cannula 7/8 (87.5%) 2/5 (40%)
Invasive ventilation 0 3/5 (60%)
COVID-19, coronavirus disease 2019
Continuous variables were examined for normality by Kolmogorov-Smirnov test. Continuous variables with normal distribution are shown mean ± standard
deviation (SD). Group comparisons were performed using independent two-sample t-test. Continuous non-normal distribution variables are shown as the median
interquartile range, and Mann-Whitney U tests were used to compare the differences between groups. Categorical variables are shown as numbers (percentages).
Chi-squared tests and Fisher’s exact test were used to compare categorical data in different groups
aDose of corticosteroid was calculated based on methylprednisolone
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increase was significant, but there was no difference be-
tween the two groups. Therefore, corticosteroid can be
free from the stigma of inhibition of viral clearance for
using corticosteroids in patients with severe COVID-1.
Our findings were consistent with the results of a recent
study [22].
As corticosteroids generally suppress the immune sys-
tem response, there is a concern that they can accelerate
secondary infections and cause many complications such
as diabetes, psychosis, and avascular necrosis [36]. In
our study, we assessed the patients’ initial severity and
response to corticosteroid using procalcitonin, CRP, and
LDH, as shown in Table 3, which were relatively well-
studied regarding the predictability of severity [7].
Patients with lymphopenia recovered, and inflammatory
parameters such as ferritin, CRP, and procalcitonin also
improved after corticosteroid use in both groups, al-
though there was no difference between the two groups.
Corticosteroid-related complications were not noted.
The mean length of hospital stay for COVID-19 pa-
tients varies from 4 to 11 days, and those with severe
and life-threatening cases of COVID-19 remain hospital-
ized for longer periods [3, 37]. In our study, the early
use group stayed in the hospital for 26 days, whereas the
late use group styed for 53.9 days. Early corticosteroid
use within 10 days after diagnosis did not reduce mortal-
ity but reduced hospital stay compared to late cortico-
steroid use. Therefore, it is important to use
corticosteroids in patients with severe COVID-19 at the
most appropriate time.
Our study had several limitations. First, the sample
size was small. It is important to note that the number
of patients with severe COVID-19 in South Korea is
relatively low compared to other countries around the
world. For this reason, the sample size was limited, des-
pite the participation of many tertiary hospitals in this
study. To overcome this, we further analyzed clinical
outcome and confirmed that it was meaningful (power
of time from diagnosis to discharge, time from symptom
to discharge, and lenth of hospital stay = 0.97, 0.967, and
0.997). The linear mixed model is exploratory, and fur-
ther research is needed by increasing the sample size.
Second, there was insufficient data on the clinical symp-
toms and missing laboratory findings. Third, since our
study was performed retrospectively, some confounders
could not be excluded. Both the dose and duration of
corticosteroid use in the study varied for each patient.
Fourth, the 10-day-based group was a relatively random
request, and it should be further divided into subgroups
in follow-up studies. Therefore, further large-scale stud-
ies in patients with severe COVID-19 are required. Fifth,
the initial Ct values between the two groups were differ-
ent. The difference in initial Ct values suggest that pa-
tients in the two groups may have different
inflammation status, and this could have affected the
Fig. 1 Comparison of clinical response after corticosteroid use. A
Changes in mean PaFiO2 ratio B Changes in mean CRP. Means were
calculated and compared between groups at each time point using
a linear mixed model. Error bars represent standard error. CRP,
C-reactive protein
Table 4 Clinical outcomes in the early use and late use groups
Early use group (n = 12) Late use group (n = 10) p-value
Time from diagnosis to discharge 27.8 ± 12.2 57.4 ± 22.5 0.024
Time from symptom to PCR-negative 25.0 (22.0–38.0) 37.5 ± (28.0–50.0) 0.190
Time from symptom to discharge 32.4 ± 13.1 60.0 ± 21.5 0.030
Time from corticosteroid use to discharge 25.6 ± 12.4 46.3 ± 22.7 0.096
Length of hospital stay 26.0 ± 11.4 53.9 ± 11.4 0.033
Overall mortality, No./Total (%) 1/12 (8.3%) 3/10 (30%) 0.293
PCR polymerase chain reaction
Continuous variables with normal distribution are shown as mean ± SD. Group comparisons were performed using independent sample t-test. Continuous non-
normal distribution variables are shown as median interquartile range. and Mann-Whitney tests were used to compare the difference between groups
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outcomes in terms of steroids inhibiting inflammation.
However, the lowest Ct value in the late use group was
the same as that in the early use group. Sixth, most of
the corticosteroids used in this study were methylpred-
nisolone, rather than dexamethasone or hydrocortisone.
Because the rationale for using dexamethasone is clear,
many studies using other steroids have not been done.
However recent studies have shown that methylprednis-
olone is not inferior to using dexamethasone [20].
Despite these limitations, our study provides valuable
information on the clinical outcomes of using corticoste-
roids in patients with severe COVID-19. The results of
this study supported the notion that corticosteroids can
be a potential treatment option for severe COVID-19,
and that it can be beneficial to use corticosteroids early
within 10 days in severe COVID-19 patients.
Conclusions
In conclusion, corticosteroids can be one of the treat-
ment options for patients with severe COVID-19, and
early use of corticosteroids showed favorable clinical
outcomes which are related to a reduction in the length
of hospital stay.
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